Latest Commercialization News

Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.

Locksley Resources has ceased active exploration at its US critical minerals projects following a technical review and a sharp drop in antimony prices, opting to maintain claims on a low-cost basis while reassessing its hydrometallurgical technology partnership.

The Calmer Co. has locked in an exclusive global distribution agreement for its kava extract ingredients, underpinning a potential A$25 million revenue stream over three years across key markets including the US and ASEAN.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

Steadfast Group's consortium reconfirms $6 per share cash offer, extending exclusivity to 21 August amid final due diligence.

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.

Audinate Group Limited reported a 15% revenue increase driven by its expanding Dante ecosystem and Iris acquisition, but underlying EBITDA losses widened amid restructuring and investment costs.

Hazer Group and KBR have secured a paid pre-feasibility study with a leading Japanese power utility to explore large-scale deployment of methane pyrolysis technology, reinforcing Hazer's foothold in Japan's clean hydrogen market.

Aurizon lifted FY2026 underlying EBITDA by 9% to $1.72 billion, boosted by strong Bulk growth and regulatory gains, while locking in a major Queensland coal haulage contract with BHP Mitsubishi Alliance.

GWA Group posted modest revenue and earnings growth in FY26, driven by volume gains across Australia, New Zealand, and the UK, while raising dividends and advancing strategic priorities despite challenging market conditions.

Celsius Resources faces a lifted court protection on its 40% MMCI stake amid disputes over capital increases and a contested copper offtake deal with Kiri Industries, setting the stage for arbitration.

Temas Resources posted a CAD 2.63 million loss for H1 2026, driven by ramped-up exploration and RCL technology development, while securing $1.5 million in fresh funding and signing initial RCL licensing contracts.